Antiemetics Drugs Market By Drug Class (Serotonin 5-HT3 receptor antagonists, Dopamine D2 receptor antagonists, Antihistamines H1 receptor antagonists, Neurokinin-1 NK1 receptor antagonists, Cannabinoids, Benzodiazepines adjunct therapy, Corticosteroids adjunct therapy, Others), By Route of Administration (Oral, Parenteral, Transdermal, Rectal), By Application (Chemotherapy-induced nausea and vomiting CINV, Postoperative nausea and vomiting PONV, Motion sickness, Gastroenteritis and food poisoning, Morning sickness pregnancy-related nausea and vomiting, Vestibular disorders, Other), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug stores), and By End-user (Hospitals, Clinics, Homecare settings, Ambulatory Surgical Centers (ASCs)), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Antiemetics Drugs Market accounted for USD 7.94 Billion in 2024 and is expected to reach USD 15.07 Billion by 2035, growing at a CAGR of around 6.00% between 2025 and 2035. The Antiemetics Drugs Market categorizes the drugs by target medications for preventing and treating chemotherapy, surgery, motion sickness, pregnancy, and gastrointestinal diseases. Fueled by inclinations in cancer, endodontic cases that are associated with the general increase in age, and surgical procedures, the market is growing progressively. Several companies remain committed to research & development of better formulations such as serotonin and NK1 receptor antagonists. Oral, injectable, and transdermal administration systems contribute to the improvement of patient compliance. North America holds the largest market share, while Europe and Asia-Pacific follow, with Asia-Pacific being the fastest growing due to the modern developments in the healthcare industry. Online pharmacies and retail expansion drive accessibility. It was noted that the policies, such as regulatory approval and generic competition, impact the issue of pricing. It is possible, to some extent, to state that future growth lies in innovation and new markets.

Report Scope:

Market Dynamics

Increasing chemotherapy cases drive demand for effective antiemetic treatments worldwide.

The global incidence of cancer has risen over the years, and with it the increase in the number of people receiving chemotherapy, since it is a common treatment for cancer, mostly comes with side effects such as nausea and vomiting. This has made it necessary to have better antiemetic drugs that would help the patient feel comfortable and continue with the medication. There have been some newer formulations for the management of CINV, including serotonin (5-HT3) and neurokinin-1 (NK-1) antagonists used as single agents or in combination with other antiemetic drugs. The approval of newer antiemetic agents also plays a significant part in driving market growth.

These are the main reasons behind this demand, hence the increasing proportion of the aging population and the incidence of cancer cases. Also, the supportive care guideline on nausea illustrates how it should be preventatively addressed in oncology patients. Pharmaceutical industries are therefore focusing on research to formulate newer, more effective, and longer-lasting antiemetics. This puts patients in a position to access the drugs easily since they have the prescription antiemetics as well as the OTC drugs. Rising knowledge of chemotherapy-induced nausea and betterment in the healthcare system is also contributing to market growth globally. For this reason, the growth in the sale of antiemetic drugs will remain steady in this market in the upcoming years.

Expanding oncology treatments boosts the demand for nausea-preventing medications.

The advancement in cancer therapies such as chemotherapy, radiation, and targeted therapies has highly contributed to the need for antiemetic drugs. CINV continues to rank among the most unpleasant experiences, which is why several antiemetic agents are applied. New concepts for cancer treatment plans call for higher and longer dose-intensity treatments, which increases the importance of managing nausea side effects. Antiemetics that are in the process of being developed by pharmaceutical firms to improve the quality of life of patients are serotonin (5-HT3) and neurokinin-1 (NK1) receptor antagonists. This aspect has seen more formulation approvals from the regulatory agencies to enhance efficacy and minimize the side effects.

Better recognition of the oncologists and patients about nausea prophylaxis has increased prescription frequency. The inclusion of antiemetics under supportive care demonstrates the importance of these drugs in the treatment of cancer. Moreover, the essential differences of oral, injectable, and transdermal antiemetics are also available to meet various needs in the patients. This is so because the global population is aging and thus experiencing a higher incidence of cancer, hence further enlarging the Antiemetics Drugs Market. As this industry continues to develop, increased research is done with projections to steady the market in the future years.

High drug development costs and extensive research, clinical trials, and regulatory approvals increase expenses.

One of the major challenges that affect the Antiemetics Drugs Market is the high costs of drug development and production since clinical development and research, coupled with attaining administrative approval, is a capital-intensive process. Several phases are required by pharmaceutical companies to determine the efficiency and safety of drugs, which results in a time-consuming drug development process and high costs. As per the regulations provided by Baxter agencies like the FDA as well as EMA, the costs are the icing on the cake due to compliance. However, unfamiliarity with the adverse effects of trials can lead to financial losses and delayed introduction of related products into the market.

This also affects the pricing in that research and other related innovations are pricey, which makes some treatments costly to consumers. It was also established that small and mid-sized pharmaceutical firms face challenges of funding and hence are usually slow in developing new antiemetics into the market. Patenting also becomes an issue here since the companies attract more costs that include the expenses on the rights to intellectual property. This is brought by costly manufacturing, quality control, and distribution, which also form part of the expenses. Thus, some economic factors may hinder the evolution of novel and eventually more effective antiemetic compounds. Therefore, expensive development stifles the market and its accessibility across the board for both the firm and patients.

Rising cancer cases drive demand for chemotherapy-induced nausea and vomiting (CINV) treatments globally.

There has been a growing incidence of cancer globally, and therefore there is a high demand for antiemetic agents to manage CINV. Since millions of patients receive chemotherapy every year, there is a need to have good antiemetic drugs to improve the quality of the treatment. The development of 5-HT3 receptor antagonists, neurokinin-1 (NK1) receptor antagonists, and corticosteroids has greatly improved the management of CINV. Pharmaceutical developments and new drug forms have enhanced outcomes with fewer negative side effects. Moreover, government policies and health care subsidies are increasing the availability of novel antiemetics.

Telemedicine and online stores for various pharmaceuticals bring an added advantage in the accessibility of drugs. The new approach of using cannabinoids as antiemetics brings new prospects. For this reason, R&D investments and clinical trials have been spearheading advancement in the therapy for CINV. With cancer incidence increasing in the world, there is a need for better and cheaper antiemetic drugs to be developed.

Advancements in drug formulations enhance efficacy, reducing side effects and improving patient compliance.

This has ensured that the advanced drug formulation for antiemetic medications is more effective than before and has minimized severe side effects, hence enhancing compliance from the patients. Extended-release formulations mean that the treatments can work for a longer period, and the patient will not have to keep on taking drops continually. ODTs and transdermal patches are also considered for patients having problems swallowing solid dosage forms, particularly those taking other oral medications. Intravenous (IV) and subcutaneous injections are effective routes of administering medication for serious nausea. Two receptor targets of passage are serotonin (5-HT3) and neurokinin-1 (NK1) receptors, which play a significant role in enhancing combined treatments.

The increase in the application of nanotechnology in drug delivery enhances bioavailability and sharpens the action area. Less sedation and side effects in the stomach make the patient compliant. Pharmacogenomics and personalized medicine are two important concepts that focus on treatment according to patient reactions. Subdued regulatory measures and market penetration led to an increased availability of new forms of the bolamitriptyline. All these developments taken together enhance the general well-being of patients afflicted with this ailment and also improve their general quality of life in the management of nausea.

Industry Experts Opinion

“They emphasized 2024 as a ‘year of execution’ for the company. Acknowledged Pfizer's struggles in 2023 and stated that the company will focus on leveraging acquisitions, such as its $43 billion buyout of Seagen, and advancing its drug pipeline. Bourla also highlighted Pfizer’s goal of strengthening commercial operations and improving the performance of new drug launches.”

• Albert Bourla, CEO of Pfizer​

Segment Analysis

Based on the Drug Class, the Antiemetics Drugs Market is classified into serotonin 5-HT3 receptor antagonists, dopamine D2 receptor antagonists, antihistamines, neurokinin-1 (NK1) receptor antagonists, cannabinoids, benzodiazepines, and corticosteroids. The selective serotonin 5-HT3 receptor antagonists, such as ondansetron, predominate because of their efficacy in treating CINV. Metoclopramide is a commonly used dopamine D2 antagonist that is prescribed for several conditions, including gastroenteritis and postoperative nausea. Antihistamines like promethazine address motion sickness and vestibular disorders. NK1 receptor antagonists, specifically aprepitant, should be used preferentially for severe nausea cases. Cannabinoids like dronabinol gain traction for chemotherapy patients. Benzodiazepines and corticosteroids are other ancillary drugs used. The introduction of new formulations and prescription of different drugs contribute to the market growth.

Based on the Application, the Antiemetics Drugs Market is classified into CINV, PONV, motion sickness, gastroenteritis, morning sickness, and vestibular disorder. CINV is the largest due to the increased incidence and prevalence of cancer with chemotherapy fostering the use of serotonin 5-HT3 and NK1 receptors. Thus, PONV remains a significant portion and grows due to the constant rise in surgical procedures globally. Among motion-related illnesses, antihistamines that are useful in treating motion sickness are expected to experience an unbroken demand among the traveling population. Before, we saw that gastroenteritis increases the prescription of antiemetic drugs within 24 hours, which are mainly dopamine antagonists. This is due to some aspects, such as the treatment of morning sickness, that are popular among pregnant women, which in turn fuels the market. They are mainly used in the treatment of vestibular disorders, which cause patients to seek antihistamines and benzodiazepines. Growing awareness and improved drug accessibility support overall market expansion.

Regional Analysis

North America holds the major share in the global Antiemetics Drugs Market because of the high occurrence of cancer and an increasing number of surgeries, coupled with well-equipped healthcare facilities. Firstly, the USA is the dominant country in the region owing to the well-developed pharmaceutical industry, innovative demand for new antiemetics, and general availability of prescription and over-the-counter drugs. That is why such companies as Merck and Pfizer are great for the market because they contribute to the innovation and accessibility of drugs. Canada also plays a role, in a population that is aging and increasing incidences of chemotherapy-induced nausea and vomiting (CINV). This has been due to high healthcare spending and favorable reforms and policies toward reimbursement of bills in the market. This is due to the availability of easy access through Internet pharmacies and new retail chain stores. However, the entrance of generic medication and stringent FDA regulation affect the price and approval of most drugs. Future growth is expected by targeting novel drug formulations and the idea of delivering medicine to a particular patient.

The Asia-Pacific Antiemetics Drugs Market is the fastest enlarging due to the growth in cancer incidence, burgeoning surgical operations, and improving health care. Regions such as China, India, and Japan feel pressure due to the increased affordability of more advanced treatments and the enhancement of people’s awareness levels about nausea and vomiting. The factors that augment the demand of the market are increasing urbanization, increasing per capita income, and the government's focus on improving healthcare facilities. Chemotherapy's commonality and the higher incidences of gastrointestinal disorders also boost the market for antiemetics. Moreover, the market is boosted by the production of generic drugs and a favorable regulatory environment. A convenient way of accessing the drugs is through the internet through online pharmacies, and such retail expansion has seen the Asia-Pacific region at the forefront of the antiemetics market.

 Competitive Landscape

The Antiemetics Drugs Market is a highly saturated one, and the main competitors are focused on product development, mergers and acquisitions, and market penetration. Some of the leading companies that are involved in the production of this product are GlaxoSmithKline, Merck & Co., Pfizer, Novartis, Johnson & Johnson, Sanofi, Bristol-Myers Squibb, and Eisai Co., Ltd. These companies explore new forms of the drugs, including extended-release antiemetics and combinations with other drugs for better results and compliance. Joint ventures, collaborations, acquisitions, and mergers are some of the familiar business development approaches to enhancing market position and the variety of products offered.

Over the years, big brand-name drugs were subjected to patent expiration, thereby provoking and breaking the dominance of generic manufacturers in terms of pricing. North America and Europe still hold the largest share due to their constant investment in research and development. Asia-Pacific is a rising market due to increased healthcare facilities and growing cancer incidences. Among the key competitive drivers, are regulatory differences in pricing, the legalization of online pharmacies, and the availability of regulatory certificates. Businesses are also continuing to look for biologics and cannabinoids in the future of the target market.

Antiemetics Drugs Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In October 2023, Astellas Pharma Inc. showcased research findings at the European Society for Medical Oncology (ESMO) Congress 2023. The presentation included an abstract highlighting the impact of antiemetics on gastric injury and emesis frequency in ferrets. Such informative presentations by key industry players are anticipated to enhance awareness about antiemetic drugs, potentially fostering market growth in the forecast period.
• In January 2023, Glenmark Pharmaceuticals Ltd introduced AKYNZEO I.V., an innovative intravenous injection formulation in the Indian market. This medication serves as an effective solution for preventing chemotherapy-induced vomiting and nausea.

Frequently Asked Questions (FAQs)